Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 419

1.

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation.

Rotunno G, Mannarelli C, Brogi G, Pacilli A, Gesullo F, Mannelli F, Fiaccabrino S, Sordi B, Paoli C, Marone I, Rumi E, Manfredini R, Barosi G, Cazzola M, Vannucchi AM, Guglielmelli P.

Blood. 2019 May 10. pii: blood.2018879536. doi: 10.1182/blood.2018879536. [Epub ahead of print] No abstract available.

PMID:
31076447
2.

NanoR: A user-friendly R package to analyze and compare nanopore sequencing data.

Bolognini D, Bartalucci N, Mingrino A, Vannucchi AM, Magi A.

PLoS One. 2019 May 9;14(5):e0216471. doi: 10.1371/journal.pone.0216471. eCollection 2019.

3.

Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis.

Mannelli F, Gesullo F, Rotunno G, Pacilli A, Bencini S, Annunziato F, Zanotti R, Scaffidi L, Giona F, Santopietro M, Grifoni F, Pieri L, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2019 May 6. doi: 10.1002/ajh.25506. [Epub ahead of print]

PMID:
31056768
4.

Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data.

Magi A, Bolognini D, Bartalucci N, Mingrino A, Semeraro R, Giovannini L, Bonifacio S, Parrini D, Pelo E, Mannelli F, Guglielmelli P, Vannucchi AM.

Bioinformatics. 2019 Apr 5. pii: btz241. doi: 10.1093/bioinformatics/btz241. [Epub ahead of print]

PMID:
30949684
5.

Comments on pre-fibrotic myelofibrosis and how should it be managed.

Barbui T, Thiele J, Gisslinger H, Orazi A, Vannucchi AM, Gianelli U, Beham-Schmid C, Tefferi A.

Br J Haematol. 2019 Mar 7. doi: 10.1111/bjh.15840. [Epub ahead of print] No abstract available.

PMID:
30847907
6.

CircRNAs Are Here to Stay: A Perspective on the MLL Recombinome.

Dal Molin A, Bresolin S, Gaffo E, Tretti C, Boldrin E, Meyer LH, Guglielmelli P, Vannucchi AM, Te Kronnie G, Bortoluzzi S.

Front Genet. 2019 Feb 13;10:88. doi: 10.3389/fgene.2019.00088. eCollection 2019.

7.

Validation of the Mayo alliance prognostic system for mastocytosis.

Mannelli F, Gesullo F, Rotunno G, Pacilli A, Pieri L, Guglielmelli P, Vannucchi AM.

Blood Cancer J. 2019 Feb 11;9(2):18. doi: 10.1038/s41408-019-0179-7. No abstract available.

8.

The JAK2 46/1 (GGCC) MPN-predisposing haplotype: A risky haplotype, after all.

Vannucchi AM, Guglielmelli P.

Am J Hematol. 2019 Mar;94(3):283-285. doi: 10.1002/ajh.25367. Epub 2018 Dec 18. No abstract available.

PMID:
30499143
9.

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera.

Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM.

Blood Cancer J. 2018 Nov 26;8(12):124. doi: 10.1038/s41408-018-0161-9. No abstract available.

10.

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.

Pacilli A, Rotunno G, Mannarelli C, Fanelli T, Pancrazzi A, Contini E, Mannelli F, Gesullo F, Bartalucci N, Fattori GC, Paoli C, Vannucchi AM, Guglielmelli P.

Blood Cancer J. 2018 Nov 22;8(12):122. doi: 10.1038/s41408-018-0152-x.

11.

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.

Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, Gisslinger H.

Haematologica. 2019 May;104(5):947-954. doi: 10.3324/haematol.2018.204602. Epub 2018 Nov 15.

12.

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.

De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Nov 12;8(11):112. doi: 10.1038/s41408-018-0151-y.

13.

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.

Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A.

Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245.

14.

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms.

Barbui T, Finazzi G, Vannucchi AM, De Stefano V.

Blood Cancer J. 2018 Nov 7;8(11):103. doi: 10.1038/s41408-018-0143-y. No abstract available.

15.

Prefibrotic myelofibrosis: treatment algorithm 2018.

Finazzi G, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Nov 7;8(11):104. doi: 10.1038/s41408-018-0142-z. Review.

16.

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ.

N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.

17.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.

Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. No abstract available.

18.

Response to "Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions" by Heidel et al.

Barosi G, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barbui T.

Leukemia. 2018 Dec;32(12):2727-2728. doi: 10.1038/s41375-018-0259-x. Epub 2018 Sep 28. No abstract available.

PMID:
30267006
19.

Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis.

Rossi C, Zini R, Rontauroli S, Ruberti S, Prudente Z, Barbieri G, Bianchi E, Salati S, Genovese E, Bartalucci N, Guglielmelli P, Tagliafico E, Rosti V, Barosi G, Vannucchi AM, Manfredini R; AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative) investigators.

Mol Oncol. 2018 Dec;12(12):2102-2123. doi: 10.1002/1878-0261.12387. Epub 2018 Nov 16.

20.

Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis.

Chorzalska A, Morgan J, Ahsan N, Treaba DO, Olszewski AJ, Petersen M, Kingston N, Cheng Y, Lombardo K, Schorl C, Yu X, Zini R, Pacilli A, Tepper A, Coburn J, Hryniewicz-Jankowska A, Zhao TC, Oancea E, Reagan JL, Liang O, Kotula L, Quesenberry PJ, Gruppuso PA, Manfredini R, Vannucchi AM, Dubielecka PM.

Blood. 2018 Nov 8;132(19):2053-2066. doi: 10.1182/blood-2018-05-848408. Epub 2018 Sep 13.

21.

Myelofibrosis Treatment Algorithm 2018.

Tefferi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Blood Cancer J. 2018 Jul 31;8(8):72. doi: 10.1038/s41408-018-0109-0. Review.

22.

Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera.

Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barosi G.

Leukemia. 2018 Sep;32(9):2077-2081. doi: 10.1038/s41375-018-0199-5. Epub 2018 Jun 28. No abstract available.

PMID:
29955128
23.

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting.

De Stefano V, Rocca B, Tosetto A, Soldati D, Petrucci G, Beggiato E, Bertozzi I, Betti S, Carli G, Carpenedo M, Cattaneo D, Cavalca V, Dragani A, Elli E, Finazzi G, Iurlo A, Lanzarone G, Lissandrini L, Palandri F, Paoli C, Rambaldi A, Ranalli P, Randi ML, Ricco A, Rossi E, Ruggeri M, Specchia G, Timillero A, Turnu L, Vianelli N, Vannucchi AM, Rodeghiero F, Patrono C.

Blood Cancer J. 2018 Jun 1;8(6):49. doi: 10.1038/s41408-018-0078-3.

24.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. No abstract available.

PMID:
29734070
25.

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.

Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM.

J Clin Oncol. 2018 Jun 10;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867. Epub 2018 Apr 30. No abstract available.

PMID:
29708808
26.

A case of disseminated blastic plasmocytoid dendritic cell neoplasm.

Loscocco GG, Piccini M, Vergoni F, Vannucchi AM, Bosi A.

Am J Hematol. 2018 Nov;93(11):1433-1434. doi: 10.1002/ajh.25109. Epub 2018 Jul 24. No abstract available.

PMID:
29664121
27.

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM.

Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.

28.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5. No abstract available.

29.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.

30.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G.

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Review.

31.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

32.

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A.

Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y. Review.

33.

The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells.

Avanzini MA, Abbonante V, Catarsi P, Dambruoso I, Mantelli M, Poletto V, Lenta E, Guglielmelli P, Croce S, Cobianchi L, Jemos B, Campanelli R, Bonetti E, Di Buduo CA, Salmoiraghi S, Villani L, Massa M, Boni M, Zappatore R, Iurlo A, Rambaldi A, Vannucchi AM, Bernasconi P, Balduini A, Barosi G, Rosti V; AGIMM Investigators.

Am J Hematol. 2018 May;93(5):615-622. doi: 10.1002/ajh.25047. Epub 2018 Feb 8.

34.

Polycythemia vera treatment algorithm 2018.

Tefferi A, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Jan 10;8(1):3. doi: 10.1038/s41408-017-0042-7. Review.

35.

Essential thrombocythemia treatment algorithm 2018.

Tefferi A, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Jan 10;8(1):2. doi: 10.1038/s41408-017-0041-8. Review.

36.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.

Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.

PMID:
29275119
37.

JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease.

Tefferi A, Lavu S, Mudireddy M, Lasho TL, Finke CM, Gangat N, Pardanani A, Hanson CA, Mannarelli C, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2018 Aug;93(4):E93-E96. doi: 10.1002/ajh.25017. No abstract available.

PMID:
29274140
38.

Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation.

Salati S, Prudente Z, Genovese E, Pennucci V, Rontauroli S, Bartalucci N, Mannarelli C, Ruberti S, Zini R, Rossi C, Bianchi E, Guglielmelli P, Tagliafico E, Vannucchi AM, Manfredini R.

Stem Cells Dev. 2017 Dec 19. doi: 10.1089/scd.2017.0137. [Epub ahead of print]

PMID:
29258411
39.

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis.

Bartalucci N, Calabresi L, Balliu M, Martinelli S, Rossi MC, Villeval JL, Annunziato F, Guglielmelli P, Vannucchi AM.

Oncotarget. 2017 May 22;8(57):96710-96724. doi: 10.18632/oncotarget.18073. eCollection 2017 Nov 14.

40.

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A.

J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.

PMID:
29226763
41.

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Vannucchi AM, Guglielmelli P.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):480-488. doi: 10.1182/asheducation-2017.1.480. Review.

42.

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.

Zini R, Guglielmelli P, Pietra D, Rumi E, Rossi C, Rontauroli S, Genovese E, Fanelli T, Calabresi L, Bianchi E, Salati S, Cazzola M, Tagliafico E, Vannucchi AM, Manfredini R; AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators.

Blood Cancer J. 2017 Dec 8;7(12):638. doi: 10.1038/s41408-017-0010-2.

43.

Polycythemia vera and essential thrombocythemia: algorithmic approach.

Vannucchi AM, Guglielmelli P, Tefferi A.

Curr Opin Hematol. 2018 Mar;25(2):112-119. doi: 10.1097/MOH.0000000000000402. Review.

PMID:
29194068
44.

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.

Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Mannarelli C, Fanelli T, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2018 Mar;93(3):348-355. doi: 10.1002/ajh.24978. Epub 2017 Dec 18.

45.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
46.

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V.

J Hematol Oncol. 2017 Sep 29;10(1):156. doi: 10.1186/s13045-017-0527-7.

47.

Traffic lights for ruxolitinib.

Vannucchi AM, Guglielmelli P.

Blood. 2017 Aug 31;130(9):1075-1077. doi: 10.1182/blood-2017-07-795880. No abstract available.

48.

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.

Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN.

Leuk Res. 2017 Oct;61:6-9. doi: 10.1016/j.leukres.2017.08.002. Epub 2017 Aug 10.

PMID:
28843161
49.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.

Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21. No abstract available.

50.

Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients.

Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Coltro G, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2017 Nov;92(11):1193-1197. doi: 10.1002/ajh.24882. Epub 2017 Aug 28.

Supplemental Content

Loading ...
Support Center